The FDA has approved an ingestible event marker from the privately-held digital health company etectRx, as its rival “digital pill” company Proteus faces financial difficulties. Florida-based ...
In its second attempt, Takeda has secured FDA approval for Eohilia ... antibody Dupixent (dupilumab), which was approved for the condition in 2022. Faced with the cost of a second trial, the ...
The FDA has granted approval to revumenib for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia. 1 Data from the phase 1/2 AUGMENT-101 trial, as ...
Eladocagene exuparvovec is the first US-approved gene therapy for AADC deficiency, administered directly to the brain. Clinical trials showed significant motor and cognitive improvements ...